万赛维怎么吃？

It is a drug launched by the Swiss company Roche. It is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients. The therapeutic effect of the drug is remarkable, and it can significantly delay the survival period of patients and improve their quality of life. So how should patients with different symptoms use this medicine?

Note: The basic requirement to avoid overdose is to strictly follow the recommended dosage.

Standard dosage: Vancevir is administered orally and should be taken with food. Vansavir can be rapidly and massively converted into ganciclovir. The bioavailability of Vancevir as measured by ganciclovir is 10 times higher than that of ganciclovir capsules, therefore the Vancevir dosage and usage instructions described below should be strictly adhered to.

Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity.

Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis.

Prevention of CMV infection in transplant patients: For patients who have received solid organ transplants, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Specific Dosage Guidelines

Patients with renal insufficiency: Serum creatinine or creatinine clearance levels should be monitored closely. Dosage adjustments should be made based on creatinine clearance as shown below.

For CrCl ≥ (greater than or equal to) 60mL/min, the induction dose is 900mg, twice a day; the maintenance dose is 900mg, once a day.

For CrCl 40-59mL/min, the induction dose is 450mg, twice a day; the maintenance dose is 450mg, once a day.

If the CrCl is 25-39mL/min, the induction dose is 900mg, once a day; the maintenance dose is 900mg, once every other day.

For CrCl 10-24mL/min, the induction dose is 900mg, once every other day; the maintenance dose is 900mg, twice a week.

The creatinine clearance rate can be estimated based on serum creatinine according to the following formula:

Male = [140-age (years) x weight (kg) ÷ (72) x [0.011 x serum creatinine (umol/L)]. Female = 0.85 × male value.

Patients undergoing hemodialysis: For patients undergoing hemodialysis (CrCl<10mL/min), no recommended dose can be given, so Vancevi cannot be used in such patients.

Cases of severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, myelosuppression and aplastic anemia have occurred in patients treated with: (or cyclovir). Do not start treatment with Vancevir if the neutrophil count is less than 500/uL, the platelet count is less than 25,000/uL, or the hemoglobin is less than 8 g/dl.